¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"magnetization transfer ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • charge to mass ratio
    ÀüÇÏ´ëÁú·®ºñ
  • child-woman ratio
    ¸ð¾ÆºñÀ²
  • dependency ratio
    ºÎ¾çºñ
  • depth to width ratio
    ±íÀÌ´ë³Êºñºñ
  • dextrose-nitrogen ratio
    Æ÷µµ´çÁú¼Òºñ
  • dilution ratio
    Èñ¼®ºñ
  • disease odds ratio
    Áúº´±³Â÷ºñ, Áúº´½Â»êºñ
  • distribution ratio
    ºÐÆ÷ºñÀ²
  • exposure ratio
    ³ëÃâºñÀ²
  • exposure-odds ratio
    ³ëÃâ±³Â÷ºñ
  • extraction ratio
    ÃßÃâ·ü
  • fetal death ratio
    žƻç¸Áºñ
  • gyromagnetic ratio
    ÀÚ±âȸÀüºñ
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²
  • heart lung ratio
    ½ÉÆóºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • zygote intrafallopian transfer
    Á¢ÇÕÀÚÀڱðü³»À̽Ä, Á¢ÇÕüÀڱðü³»Àü´Þ
  • A-G ratio
    (¢¡albumin-globulin ratio) ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • abortion ratio
    À¯»êºñ
  • age-dependency ratio
    ¿¬·ÉºÎ¾çºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü
  • air pollution ratio
    ´ë±â¿À¿°·ü
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×Ç÷ûºñ
  • albumin-globulin ratio
    ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×´¢¼ÒÁú¼ÒÅ©·¹¾ÆÆ¼´Ñºñ
  • body-weight ratio
    üÁß½ÅÀåºñ, ¸ö¹«°ÔŰºñ
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • innervation ratio
    ½Å°æÁö¹èºñ(¡­Ýï).
  • inspiratory expiratory ratio
    ÈíÈ£±â´ëºñ.
  • phase ratio
    »óºñ(ßÓÝï).
  • primary sex ratio
    ÀÏÂ÷¼º ºñ(ÊÙËÛËÓ).
  • ratio
    ºñ(ËÓ).
  • ratio
    ºñ(Ýï)
  • ratio estimate
    ºñÃßÁ¤·®(ËÓÌ§ËøËâ).
  • ratio intelligence qoutient
    Áö´ÉºñÀ²Áö¼ö
  • ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • ratio of dependants
    ºÎ¾çºñ(ËÓËâËÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • magnetisation transfer coherence
    ÀÚÈ­ Àü´Þ °áÁý
  • mass energy transfer coefficient
    Áú·®¿¡³ÊÁöÀüÀ̰è¼ö
  • microneurovascular muscle transfer
    ¹Ì¼¼½Å°æÇ÷°ü±Ù À̽ļú
  • momentum transfer theory
    ¿îµ¿·®ÀüÀÌÀÌ·Ð.
  • muscle transfer, microneurovascular
    ¹Ì¼¼ ½Å°æÇ÷°ü±Ù À̽ļú
  • myoblast transfer theraphy
  • passive transfer
    Çǵ¿¼º Àü°¡(ù¬ÔÑàõï®Êª).
  • passive transfer test
    ¼öµ¿Àü´Þ°Ë»ç
  • placenta transfer
    ŹÝÀüÀÌ, ŹÝÅë°ú
  • placental transfer
    ŹÝÀ̵¿.
  • placental transfer
    ŹÝÀ̵¿(÷ÃÚïì¹ÔÑ)
  • radiation,linear energy transfer (let)
    ¼±»ó¿¡³ÊÁöÀüȯ(àÊß¾¡­ï®üµ)
  • replication, transfer
    Àü´Þº¹Á¦ (Çö󽺹̵åÀÇ)
  • resistance transfer factor
    ³»¼ºÀü´ÞÀÎÀÚ(Ò±àõîîÓ¹ì×í­).
  • specific transfer process
    Ư¼ö¿î¹Ý°úÁ¤.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • energy transfer
    ¿¡³ÊÁö ÀüÀÌ(ï®ì¹)
  • exciton transfer
    ¿¢½ÃÅæ ÀüÀÌ(ï®ì¹)
  • filter affinity transfer
    °Å¸£°Ô ģȭÀüÀÌ(öÑûúï®ì¹)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • infectious transfer
    °¨¿°¼º ÀÌÀü(Êïæøàõì¹ï®)
  • initiator transfer RNA
    °³½Ã(ËÒã·) Àü´Þ(îîÓ¹)RNA
  • isoacceptor transfer RNA
    µ¿Á¾¼ö³³Ã¼(ÔÒðúáôÒ¡ô÷) ÀüÀÌ(ï®ì¹)RNA
  • linear energy transfer
    ¼±Çü(àÊû¡) ¿¡³ÊÁöÀüÀÌ(ï®ì¹)
  • methionyl transfer RNA
    ¸ÞƼ¿À´Ñ Àü´Þ(îîÓ¹) RNA
  • methyl-poor transfer RNA
    °ú(Íû)¸ÞÆ¿ Àü´Þ(îîÓ¹)RNA
  • modulator transfer RNA
    Á¤Á¶ÀÚ(ïÚðàí­) Àü´Þ(îîÓ¹) RNA
  • noncollisional energy transfer
    ºñÃæµ¹(ÞªõúÔÍ)¿¡³ÊÁöÀü´Þ(îîÓ¹)
  • passive transfer
    ¼öµ¿ À̵¿(áôÔÑì¹ÔÑ)
  • phase transfer
    »óÀüÀÌ(ßÓï®ì¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
LSR lanthanide shift reagent; lecithin/ sphingomyelin ratio; left superior rectus [muscle]; liver/spleen...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
TR recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ET Embryo transfer
ET Energy transfer
EITB Enzyme Linked Immunoelectro Transfer Blot
FPT Failure of passive transfer
FTP File Transfer Protocol
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • W/P ratio
    È¥¼öºñ
    ¼®°íÀÇ ¿¬È­¿¡ »ç¿ëµÇ´Â ¹°ÀÇ ¾ç°ú ¼®°í ºÐ¸»ÀÇ ¹«°Ô ºñ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
IRI/G ratio The ratio of immunoreactive insulin to serum or plasma glucose; in hypoglycaemic states a ratio of less than 0.3 is usual with the exception of the hypoglycaemia due to insulinoma, where the ratio is often higher than 0.3.
(05 Mar 2000)
odds ratio <epidemiology> A comparison of the presence of a risk factor for disease in a sample of diseased subjects and non diseased controls. The number of people with disease who were exposed to a risk factor ( I.e. ) over those with disease who were not exposed ( Io ) divided by those without disease who were exposed ( Ne ) over those without who were not exposed ( No ). Thus OR=(I.e./Io)/(Ne/No)= I.e. No / Io Ne. This measure should be used for case control studies where we retrospectively look at risks in those with and without disease. Also known as exposure odds ratio.
(05 Dec 1998)
therapeutic ratio The ratio of the maximally tolerated dose of a drug to the minimal curative or effective dose; LD50 divided by ED50.
(05 Mar 2000)
tritium-breeding ratio <radiobiology> The amount of tritium generated by the breeding blanket of a D-T fusion reactor, divided by the amount of tritium burned in the reactor. A tritium breeding ration greater than unity is necessary for self-sufficient fueling.
(09 Oct 1997)
turn down ratio The lowest load at which a boiler will operate efficiently as compared to the boiler's maximum design load.
(05 Dec 1998)
exposure odds ratio <epidemiology> See Odds ratio.
(05 Dec 1998)
extraction ratio The fraction of a substance removed from the blood flowing through the kidney; it is calculated from the formula (A -V)/A, where A and V, respectively, are the concentrations of the substance in arterial and renal venous plasma.
(05 Mar 2000)
K:A ratio <abbreviation> Ketogenic-antiketogenic ratio.
(05 Mar 2000)
ketogenic-antiketogenic ratio The proportion between substances that form ketones in the body and those that form d-glucose.
(05 Mar 2000)
zeta sedimentation ratio The ratio of the zetacrit to the haematocrit, normally 0.41 to 0.54 (41 to 54%); it is a sensitive indicator of the erythrocyte sedimentation rate (ESR) and, unlike the latter, is unaffected by anaemia, which tends to elevate the ESR.
(05 Mar 2000)
fertility ratio A measure of the fertility of a population based on the female population in the child-bearing age-group, defined as ages 15-49 years.
(05 Mar 2000)
flux ratio The ratio of the two unidirectional fluxes through a particular boundary layer or membrane.
(05 Mar 2000)
lecithin/sphingomyelin ratio A ratio used to determine foetal pulmonary maturity, found by testing the amniotic fluid; when the lungs are mature, lecithin exceeds sphingomyelin by 2 to 1.
(05 Mar 2000)
functional terminal innervation ratio The number of muscle fibres divided by the number of axons that innervate them.
(05 Mar 2000)
low aspect ratio <physics> An aspect ratio for a torus that is small (minor radius is almost as big as major radius).
There are many fusion devices which are designed to have a low aspect ratio. Such devices look more like tractor tires than bicycle tires, as toruses go. There are reasons to believe that low aspect ratio devices will offer some advantages for a fusion reactor. Usually, ease of theoretical and/or numerical analysis is not one of these advantages.
(16 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á